Aitia’s CEO Wants You to Use AI to Do More than Designing Drugs Against Known Validated Targets
AI in the pharma R&D world isn’t just about designing better drugs against known drug targets, according to Aitia’s CEO, Colin Hill. Hear what Colin had to say on how powerful AI can be in understanding novel human causal biology, creating novel drugs, and enhancing patient selection in clinical trials. Full article on DPHARM, here. […]
Digital Twins: When AI drives progress for the pharmaceutical industry
In its inaugural edition, Servier digital magazine, Insights, features Aitia’s Gemini Digital Twins in its “Science Calling” section. The conversion of causal AI and Gemini Digital Twins with industrial expertise holds the potential to significantly expedite R&D phases and streamline the identification of new targets. In May 2023, Aitia and Servier inked a multi-year agreement […]
How Digital Twins are Transforming Medicine
What if you could test a drug candidate on people before clinical trials? What if, instead of mice, a human computer model could be the first “lab rat” to determine the efficacy of a molecule, or to provide insight into a potential drug target? Hear from our CEO, Colin Hill, as he unveils the transformative […]
Unveiling the AI Dominance in Biopharma: STAT Post JPM Conference Insights
JPM conference has echoed discussions about AI across the biopharmaceutical landscape. Catch up on key insights shared in the latest STAT article titled: “At Health Care’s Biggest Investor Conference, AI’s High Hopes Collided with Skepticism.” Sanofi’s chief executive, Paul Hudson, revealed the widespread integration of AI within the company: “More than 11,000 people across the […]
Servier and Aitia Announce a New Collaboration Focused on Parkinson’s Disease
Aitia‘s Gemini Digital Twins will help identify subpopulations of patients who could respond favorably to Servier’s LRRK2 in development treatment Suresnes (France), 08 January 2024 – Servier, an independent international pharmaceutical group, and Aitia, the leader in the application of causal AI and Digital Twins, have strengthened today their partnership by signing a new contract […]
Servier Will Apply Aitia’s Gemini Digital Twins to Parkinson’s Drug
Spotlight on our joint effort with Servier, strengthening our partnership by entering a new collaboration focused on neuroscience. The aim of this cooperation is to leverage Aitia’s Gemini Digital Twins to identify patients most likely to respond positively to Servier’s Leucine-Rich-Repeat-Kinase 2 inhibitor (LRRK2i) in development treatment for Parkinson’s disease. Read the full article on […]
Partner of Choice: Aitia and Servier Revolutionize the Landscape of Pancreatic Cancer Treatment
Spotlight on our joint effort with Servier to advance the discovery and simulation of drugs for Pancreatic Cancer. This strategic partnership aims to delve into the intricate mechanisms of this complex disease, with the goal of expediting the development of innovative therapies for individuals affected by pancreatic cancer. Read what Servier had to say about […]
Charles River and Aitia Join Forces to Harness AI and Gemini Digital Twins in Advancing Neurodegenerative and Oncology Research
Charles River Laboratories has entered into an agreement granting Aitia access to its artificial intelligence-powered drug solution platform. The objective is to expedite the development of multiple therapy programs targeting neurodegenerative diseases and oncology. Read more on the recent collaboration between Charles River and Aitia, in Fierce Biotech article. Full article available here.
Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an equity investment in Aitia as part of the agreement WILMINGTON, Mass. & Somerville, Mass. – November 13, 2023: Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia, a leader in the application of Causal AI and […]
Hear What Colin Hill had to say to Sidley on AI Use in Drug Discovery
Stephen Abreu, Sidley partner, talks to our Colin Hill about how the use of AI is revolutionizing the biotech space. Colin explains how our ability to predict and understand the actions of biological systems has historically been limited because of the complexity of “genetic circuitry,” but AI has allowed us to develop a more quantitative […]